China 
Africa 
Explore chapters and articles related to this topic
Lipid Coated Microbubbles and Nanodroplets as Tools for Biomedical Nanotechnology
Published in Vladimir Torchilin, Mansoor M Amiji, Handbook of Materials for Nanomedicine, 2011
Evan Unger, Terry O. Matsunaga
Recent treatment modalities have alluded to the emergence of docetaxel for the management of prostate cancer.22 In patients with metastatic hormone refractory prostate cancer (HRPCa), the average median time to the first skeletal-related event is 10 months19 and the average survival is less than two years.38 In a seminal trial by both the TAX 327 group and the Southwestern Oncology Group, docetaxel administered at 75 mg/m2 every three weeks resulted in a three month prolongation in survival and quality of life in men with HRPCa.26 This improvement has made docetaxel a treatment of choice in metastatic disease. Although a very promising breakthrough for management of prostatic disease, a more selective delivery of this agent to affected prostate tumors would provide the potential for improved survival and possibly cure in HRPCa.
Pleural disease induced by drugs
Published in Philippe Camus, Edward C Rosenow, Drug-induced and Iatrogenic Respiratory Disease, 2010
Docetaxel is a chemotherapeutic agent approved for the treatment of ovarian and breast cancers. The intravenous administration of docetaxel has been reported to cause myelosuppression, peripheral neuropathy and a hypersensitivity reaction. A series of five patients was reported to have docetaxel-induced pleural effusions.25 Pleural fluid analysis revealed that all the effusions were exudative with a glucose concentration similar to serum and pleural fluid pH in the alkaline range of 7.48–7.60. Cytological examination showed predominantly reactive mesothelial cells without eosinophil predominance. The effusions appeared an average of 19 weeks following the initiation of drug therapy and resolved an average of 20 weeks following drug cessation.
Design, Fabrication and Characterization of Magnetic Porous PDMS as an On-Demand Drug Delivery Device
Published in Nguyễn T. K. Thanh, Clinical Applications of Magnetic Nanoparticles, 2018
Ali Shademani, Hongbin Zhang, Mu Chiao
To assess device functionality to release a real drug, docetaxel (DTX) was selected as a well-established anticancer medication, which is used to treat several cancer diseases such as prostate, breast, gastric, head and neck and nonsmall cell lung cancer, according to the National Cancer Institute (NCI). Docetaxel has antiproliferative characteristics which inhibit cell replication leading to the death of the cancerous cells in the tumour.47 Numerous studies have demonstrated docetaxel treatment efficacy based on different treatment protocols.48–50 Inevitable side effects such as myelosuppression, neutropenia and nail toxicity have been reported.51–53
Docetaxel-loaded redox-sensitive nanoparticles self-assembling from poly(caprolactone) conjugates with disulfide-linked poly(ethylene glycol)
Published in Journal of Biomaterials Science, Polymer Edition, 2022
Yongli Shi, Chunyan Li, Mingbo Yang, Xiaofei Pan, Jie Hu
Clinically, surgical treatment is still one of the main treatment methods for the breast cancer. Besides, chemotherapy is common used as an adjunct to patients after surgery or radiation therapy to reduce the chance of recurrence [9]. However, the chemotherapeutics usually cause serious side effects, e.g. fatigue [10], depression, vomiting [11], hair loss [12], menopause [13], nausea [14], and so on. For example, docetaxel (DTX), as a derivative of paclitaxel, causes cell apoptosis by promoting the aggregation and de-polymerization of microtubules [15]. Therefore, DTX shows excellent anti-cancer activity, and it is commonly used in the treatment of breast cancer [16]. Like other anti-cancer drug, DTX also displays a dosage-depend toxicity. Its major side effect is myelosuppression [17], resulting in leukopenia. To overcome these dilemma, many smart nano-carriers are developed to targeted deliver drug into tumor cells [18,19]. It is reported that the cancer cells display low pH and redox microenvironments [20], which can be used as the stimulus to deliver chemotherapeutics intra-cellularly [21–23]. These system targeted accumulate chemotherapeutics in cancer cells, which improves the anti-cancer activity of model drugs and decrease their side effects.